10-K/A: Xenetic Biosciences Discloses Executive Pay and Related Party Deals

Xenetic Biosciences, Inc. has amended its annual report to provide detailed disclosures on executive compensation, board governance, and significant consulting agreements with related parties.

Summary

• Amended the original 10-K filing to include Part III information regarding directors, executive officers, and corporate governance.
• Reported a net loss of $2,680,860 for the fiscal year ended December 31, 2025, compared to a net loss of $3,960,275 in 2024.
• James Parslow serves as Interim CEO and CFO with a base salary of $400,000 and received a $100,000 retention bonus in 2025.
• Disclosed a $0.4 million consulting agreement with Board Chairman Dr. Dmitry Genkin for services related to the oncology program.
• Maintains a clinical trial services agreement with Peri-Ness Ltd, an entity affiliated with two directors, with estimated costs of $0.3 million.
• The aggregate market value of common stock held by non-affiliates was approximately $5,110,488 as of June 30, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update. While the narrowing net loss is positive, the heavy reliance on related-party consulting and interim leadership warrants a balanced outlook.

Positives

• Net loss narrowed by approximately 32% year-over-year, from $3.96 million to $2.68 million.
• Total Shareholder Return (TSR) showed significant improvement, rising from $30.93 in 2024 to $76.11 in 2025 based on a $100 initial investment.
• The company successfully completed an underwritten public offering in October 2025.
• Management roles are clearly defined with a separation between the Board Chair and the Interim CEO.

Negatives

• The company remains unprofitable with a multi-million dollar annual net loss.
• Significant reliance on related-party transactions, including substantial consulting fees paid to the Board Chairman.
• Noted a delinquency in Section 16(a) reporting, as Dr. Genkin has not yet filed an initial Form 3.
• The company is a 'smaller reporting company,' which may limit the depth of certain financial disclosures compared to larger peers.

Risks

• Potential conflicts of interest due to extensive related-party dealings with Pharmsynthez, SynBio, and Peri-Ness Ltd.
• Dependence on the success of the DNase-based oncology program and systemic DNase I technology.
• Reliance on a single individual, James Parslow, to fulfill the roles of Interim CEO, CFO, and Corporate Secretary.
• Regulatory risks associated with collaborative partners, such as Pharmsynthez's ongoing efforts to address deficiencies in its registration dossier for Epolong in Russia.

Future Outlook

The company is focused on advancing its systemic DNase I technology and oncology programs. It intends to file a definitive proxy statement later in 2026 and continues to monitor the regulatory progress of its technology licensed to Pharmsynthez in international markets.

Management Comments

• James Parslow received a $100,000 cash retention bonus for remaining employed with the Company for a ten-month period.
• The Board of Directors believes the current leadership structure, which separates the CEO and Board Chair roles, is the optimal structure for the Company at this time.

Industry Context

StockSavvy.ai notes that Xenetic's reliance on a lean management team and specialized consulting from board members is common among micro-cap biotechnology firms seeking to minimize overhead while advancing early-stage clinical assets.

Comparison to Industry Standards

• The Interim CEO's total compensation of $536,027 is lower than the median for established biotech CEOs but high relative to the company's $5.1 million non-affiliate market capitalization.
• The use of a $400,000 consulting fee for a non-executive Board Chair is a specific governance mechanism used by smaller firms like Cocrystal Pharma to access technical expertise.
• Audit fees of $165,000 are consistent with industry standards for smaller reporting companies listed on the Nasdaq Capital Market.

Management Changes

Corporate Governance

Legal Proceedings

• No directors or executive officers have been involved in reportable legal proceedings during the past ten years.

Related Party Transactions

• Consulting agreement with Board Chair Dr. Dmitry Genkin totaling $0.4 million in 2025.
• Clinical trial services agreement with Peri-Ness Ltd (affiliated with Dr. Genkin and Mr. Mizrahy) with $0.2 million incurred through 2025.
• Ongoing collaborative R&D and license agreements with Pharmsynthez and its subsidiary SynBio LLC.

Stakeholder Impact

• Shareholders receive increased transparency regarding executive compensation and potential conflicts of interest.
• Management is incentivized through a mix of base salary, retention bonuses, and stock options.
• Collaborative partners remain central to the company's long-term commercialization strategy.

Next Steps

• File the definitive proxy statement later in 2026.
• Dr. Genkin is expected to file the initial Form 3 to address the Section 16(a) delinquency.
• Continue clinical trial services with Peri-Ness Ltd to advance the DNase I technology program.

Key Dates

Recommendation

The company is making progress in reducing its net loss and has successfully raised capital, but the micro-cap valuation and heavy reliance on related-party consulting suggest that investors should wait for further clinical milestones before increasing exposure.

Keywords

Biotechnology, Oncology, DNase technology, PolyXen, Executive Compensation, Related Party Transactions, Clinical Trials, SEC Amendment, James Parslow, Dmitry Genkin